title: Effects of pitavastatin on adiponectin in patients with hyperlipidemia.
abstract: The effects of treatment with pitavastatin on inflammatory and platelet activation markers and adiponectin in 117 patients with hyperlipidemia were investigated to determine whether pitavastatin may prevent the progression of atherosclerotic changes in hyperlipidemic patients. Adiponectin levels prior to pitavastatin treatment in hyperlipidemic patients with and without diabetes were lower than levels in normolipidemic controls. Both total cholesterol and the low-density lipoprotein cholesterol decreased significantly after pitavastatin administration. Additionally, hyperlipidemic patients with or without type 2 diabetes exhibited a significant increase in adiponectin levels 6 months after pitavastatin treatment (diabetes: 3.52 +/- 0.80 vs. 4.52 +/- 0.71 microg/ml, p < 0.001; no diabetes: 3.48 +/- 0.71 vs. 4.23 +/- 0.82 microg/ml, p < 0.05). However, high-sensitivity C-reactive protein, platelet-derived microparticle and soluble P-selectin did not exhibit any differences before or after pitavastatin administration. Levels of adiponectin significantly increased after pitavastatin administration in the group of lower soluble P-selectin (soluble P-selectin before pitavastatin treatment <200 ng/ml). These results suggest that pitavastatin possesses an adiponectin-increasing effect in patients with hyperlipidemia and this effect is influenced by intensive platelet activation.
authors.affiliation: Second Department of Internal Medicine, Kansai Medical University, Moriguchi, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Inami
authors.forename: S
authors.initials: S
authors.lastname: Nomura
authors.forename: A
authors.initials: A
authors.lastname: Shouzu
authors.forename: S
authors.initials: S
authors.lastname: Omoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kimura
authors.forename: N
authors.initials: N
authors.lastname: Takahashi
authors.forename: A
authors.initials: A
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Nanba
authors.forename: Y
authors.initials: Y
authors.lastname: Shouda
authors.forename: T
authors.initials: T
authors.lastname: Iwasaka
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control; D002097:C-Reactive Protein / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D018450:Disease Progression; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D019007:P-Selectin / Q000097:blood; D011804:Quinolines / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D052242:Adiponectin; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019007:P-Selectin; D011804:Quinolines; D002097:C-Reactive Protein; D002784:Cholesterol; C108475:pitavastatin